
Shares of Cohance Lifesciences tumbled 6.91% to Rs 450 in Wednesday’s trading session after the company reported a sharp deterioration in its March-quarter earnings, prompting global brokerage Jefferies to downgrade the stock from “Hold” to “Underperform.” However, Goldman Sachs retained its “Buy” rating on the company.
The pharma and specialty chemicals player posted a steep 84% year-on-year drop in Q4FY26 net profit at Rs 20 crore, compared with Rs 120.4 crore in the same quarter last year. Revenue from operations also fell sharply by 26.3% YoY to Rs 619.1 crore against Rs 840.4 crore a year ago. For the full FY26, revenue stood at Rs 2,269 crore.